Preferred Label : Pamiparib;
NCIt synonyms : 5,6,7a,11-Tetraazacyclohepta(def)cyclopenta(a)fluoren-4(7H)-one, 2-Fluoro-5,8,9,10,10a,11-hexahydro-10a-methyl-,
(10aR)-; PARP Inhibitor BGB-290;
NCIt definition : An orally bioavailable inhibitor of the nuclear enzyme poly(ADP-ribose) polymerase
(PARP), with potential antineoplastic activity. Upon administration, pamiparib selectively
binds to PARP and prevents PARP-mediated repair of single-strand DNA breaks via the
base-excision repair (BER) pathway. This enhances the accumulation of DNA strand breaks,
promotes genomic instability, and eventually leads to apoptosis. PARP is activated
by single-strand DNA breaks and, subsequently, catalyzes post-translational ADP-ribosylation
of nuclear proteins which then transduce signals to recruit other proteins to repair
damaged DNA. Pamiparib may both potentiate the cytotoxicity of DNA-damaging agents
and reverse tumor cell chemo- and radioresistance.;
UNII : 8375F9S90C;
InChIKey : DENYZIUJOTUUNY-MRXNPFEDSA-N;
CAS number : 1446261-44-4;
Molecule name : BGB-290;
Origin ID : C120553;
UMLS CUI : C5139725;
Automatic exact mappings (from CISMeF team)
- Currated CISMeF NLP mapping
- Semantic type(s)
- UMLS correspondences (same concept)
- chemical_or_drug_affects_gene_product
- concept_is_in_subset
- has_target
